Targeting Bcl-2 Protein to Enhance Chemosensitivity of Hormone Refractory Prostate Cancer Cell Line, DU-145 by a Synergistic Combination of Docetaxel and Gossypol.
Objective: Docetaxel has become the standard of care for hormone-refractory prostate cancer (HRPC), however drug resistance and toxicity are still challenging in daily cancer practice. The anti-apoptotic pathway centered around the Bcl-2 protein might be one of the responsible pathways. Adding a sec...
| Publicado en: | Turkiye Klinikleri Journal of Medical Sciences Vol. 31; no. 4; pp. 859 - 867 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
Turkiye Klinikleri
Aug2011
|
| Acceso en línea: | Ver este registro en EBSCOhost |